**Specifications** \[*standardized info for the reader*\] {#s0005}
=========================================================

Image 1Organism/cell line/tissue*Homo sapiens*/primary astrocytes isolated from 14--18-week-old postmortem fetal brainSex*NA*Sequencer or array type*Illumina HumanHT-12 v4*Data format*Raw and normalized*Experimental factors*Topoisomerase I inhibition*Experimental features*Triplicate cultures of human primary astrocytes were treated with 300 nM Topotecan or 0.1% DMSO (as control), for either 24 or 48 h.*Consent*NA*Sample source location*Sydney, Australia*

Direct link to deposited data {#s0010}
=============================

[*https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90052*](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90052){#ir0010}

1. Introduction {#s0015}
===============

Topoisomerases are important for gene expression as they are required for removing DNA supercoiling generated during transcription. Topoisomerases I and II are expressed throughout the developing and adult brain [@bb0015], [@bb0020]. Interestingly, de novo variants in topoisomerase genes have been identified in patients with autism spectrum disorder (ASD), raising the possibility of a specific role of topoisomerases in brain development [@bb0025], [@bb0030]. It has recently been demonstrated that the inhibition of topoisomerase I and II in human and mouse cortical neurons leads to reduced expression levels of very long genes, over 100 kb, of which many have been implicated in ASD [@bb0005]. The effect of topoisomerases on the expression of long genes appears to be occurring at the stage of transcription elongation [@bb0005]. In addition, topoisomerase I is required for ligand-dependent enhancer activation [@bb0035] and has been shown to generate double-stranded breaks in promoter regions, which in turn are required for the expression of neuronal early-response genes [@bb0040]. The role of topoisomerases in regulating gene expression in the brain has been primarily investigated in neurons. However, accumulating evidence supports an important role for glial cells during brain development [@bb0010], [@bb0045], [@bb0050], [@bb0055], [@bb0060]. Therefore, we investigated the effect of topoisomerase I inhibition on gene expression in human primary astrocytes, in order to identify genes that may respond to topoisomerase I inhibition in a cell-type-specific manner.

2. Experimental design, materials, and methods {#s0020}
==============================================

2.1. Cell culture {#s0025}
-----------------

Human primary astrocytes were isolated from a 14--18-week-old postmortem fetal brain following therapeutic termination with informed consent, following the UNSW ethics protocol HREC 08284. Isolation was carried out as previously described [@bb0065]. Cells were cultured in RPMI 1640 medium (Life Technologies, no. 61870-036) supplemented with 10% fetal bovine serum, 1% streptomycin (10,000 μg/ml), 1% penicillin (10,000 units/ml), and 1% Fungizone (2.5 μg/ml).

2.2. Topotecan treatment {#s0030}
------------------------

Human primary astrocytes were seeded in 6-well cell culture plates at a density of 500,000 cells per well and incubated overnight at 37 °C, with 5% CO~2~. After 24 h in culture, cell were treated with either topotecan (Sigma Aldrich, no. T2705) at a final concentration of 300 nM or 0.1% DMSO as a vehicle control. Treatment was carried out in triplicate wells of a 6-well plate for 24 or 48 h.

2.3. RNA extraction {#s0035}
-------------------

Total RNA was isolated after 24 or 48 h of treatment, using a Qiagen RNeasy kit, with on-column DNA digestion.

2.4. Microarray analysis {#s0040}
------------------------

100 ng of total RNA from each RNA sample were analyzed on Illumina HumanHT-12 v4 Expression BeadChip. cDNA labeling and array hybridization were carried out at the UNSW Ramaciotti Centre for Genomics using standard Illumina protocols. Raw data were processed in R (<http://www.r-project.org>). Briefly, raw expression data were log~2~ transformed and normalized by quantile normalization using the *lumi* package [@bb0070]. Probes with intensity above the background (i.e. detection *p* value \< 0.05) in at least 3 samples were considered expressed and retained for further analysis. A total of 23,000 probes passed these criteria. Differential expression analysis was carried out using a linear model implemented in the Bioconductor package *limma*, contrasting control cells with cells treated with Topotecan for either 24 or 48 h. *p* values were adjusted for multiple testing using a Benjamini--Hochberg correction. Probes were considered differentially expressed if the corrected *p* value was \< 0.05 and the absolute fold change was \> 1.5. All analyses were carried out at probe level. Gene length for the RefSeq transcript corresponding to each probe was obtained from the UCSC table browser, refGene track for the human genome build *hg38*, downloaded 11.2016. The list of ASD-associated genes was obtained from the SFARI database\'s [@bb0075] gene scoring module and included only the "syndromic," "high confidence," and "strong candidate" genes (<https://gene.sfari.org/autdb/GS_Home.do>).

3. Results and discussion {#s0045}
=========================

We identified 3303 differentially expressed probes for cells treated with Topotecan for 24 h (1633 down-regulated and 1670 up-regulated), and 3112 differentially expressed probes at 48 h (1565 down-regulated and 1547 up-regulated). We observed a significant inverse correlation between gene length and expression change at both time points ([Fig. 1](#f0005){ref-type="fig"}; Spearman *rho* = − 0.57, *p* value = 4.73 E-252 at 24 h; Spearman *rho* = − 0.38, *p* value = 2.85 E-97 at 48 h). These results support the notion that topoisomerase I inhibition affects gene expression in a length-dependent manner, leading to down-regulation of long genes in human primary astrocytes. Of the 120 genes listed in the SFARI database as "syndromic," "high confidence," or "strong candidate," 26 genes were significantly dysregulated following Topotecan treatment at either time point ([Table 1](#t0005){ref-type="table"}). Seventy-three percent of these genes, i.e. 19 genes, were down-regulated, and only 7 genes were up-regulated. Notably, only one of the ASD genes differentially expressed in astrocytes, *CTNND2*, has been previously reported to change in expression in response to Topotecan treatment in neurons. Therefore, the present dataset identifies novel effects of topoisomerase I on ASD genes in brain cells.

This work was supported by an NHMRC project and an UNSW Brain Sciences Collaborative PhD Grant-in-Aid.

![*Length-dependent gene expression changes upon topotecan treatment.*\
*a*) Scatterplot of log~2~ fold changes at 24 h versus gene length. Each circle represents one differentially expressed gene. Red dots represent ASD genes. Red vertical line marks 100 kb.\
*b*) Boxplot of log~2~ fold changes for genes differentially expressed at 24 h, binned by gene length. Green: genes shorter than 100 kb; red: genes longer than 100 kb.](gr1){#f0005}

###### 

*ASD genes differentially expressed upon topotecan treatment.* ProbeID: Illumina Array Address ID. P value: Differential expression p-value at the corresponding time point, after multiple testing correction.

Table 1

  Gene symbol   ProbeID   log~2~ fold change   *p* value   Gene length (bp)   Time point
  ------------- --------- -------------------- ----------- ------------------ ------------
  ADSL          5870228   − 0.67               1.13E-04    20249              48 h
  ADSL          5870228   − 0.64               2.67E-03    20249              24 h
  AHI1          5860253   0.65                 2.10E-03    213794             24 h
  AHI1          5860253   0.96                 6.40E-06    213794             48 h
  ANKRD11       3370274   − 0.77               1.81E-02    222941             24 h
  BCKDK         5220347   − 0.59               3.65E-04    4498               48 h
  CTNND2        4610075   − 1.36               5.94E-03    932203             24 h
  CTNND2        4610075   − 0.93               9.41E-06    932203             48 h
  DHCR7         5360678   − 0.80               4.85E-05    14021              48 h
  DHCR7         6550048   − 0.69               1.21E-04    14021              48 h
  DMPK          3930164   0.90                 4.77E-05    12849              48 h
  EP300         7570068   0.66                 8.78E-05    87468              48 h
  HDAC4         5900468   − 1.13               4.70E-04    352782             24 h
  HDAC4         5900468   − 0.79               6.98E-05    352782             48 h
  HERC2         6130674   − 0.87               7.44E-03    211116             24 h
  KAT2B         7200703   − 0.92               2.31E-03    114373             24 h
  NFIX          5720129   − 0.60               4.00E-03    103027             24 h
  NTNG1         6940053   − 1.45               5.23E-07    344982             48 h
  NTNG1         4390333   − 1.19               6.10E-07    344982             48 h
  OCRL          60324     0.66                 7.83E-05    52279              48 h
  PRKD1         1070184   − 0.78               3.66E-03    351213             24 h
  RAI1          520561    − 0.73               2.26E-03    129979             24 h
  RPS6KA3       3370110   − 0.62               9.64E-05    116722             48 h
  SGSH          1340538   0.87                 1.18E-02    11121              24 h
  SGSH          1340538   0.94                 2.89E-05    11121              48 h
  SNX14         4260504   − 0.74               1.37E-03    88660              24 h
  SNX14         1990561   − 0.63               4.83E-03    88660              24 h
  STXBP1        6100112   0.62                 1.76E-04    80510              48 h
  STXBP1        1260564   0.84                 2.45E-05    80510              48 h
  TCF4          2510672   − 1.26               1.23E-06    366299             48 h
  TCF4          2510672   − 1.14               9.25E-04    366299             24 h
  TSC2          450376    − 0.60               6.78E-03    40826              24 h
  UBE3A         2360379   − 0.94               1.65E-03    101780             24 h
  UBE3A         1990307   − 0.93               1.38E-03    101780             24 h
  UPF3B         780743    1.19                 1.87E-06    19003              48 h
  UPF3B         4640239   1.21                 1.63E-06    19003              48 h
  UPF3B         780743    1.38                 2.40E-04    19003              24 h
  UPF3B         4640239   1.43                 1.24E-04    19003              24 h
  USP7          4640670   − 0.70               1.79E-03    71391              24 h
  USP7          4640670   − 0.60               1.42E-04    71391              48 h
  ZBTB20        3440189   − 0.73               2.26E-03    832781             24 h
  ZBTB20        3440189   − 0.64               1.57E-04    832781             48 h
